Inhibikase Therapeutics(IKT)
WILMINGTON, DEBiotechnology
Focus: Inhibikase Therapeutics is a public biotech company focused on therapeutic vaccines and small-molecule treatments in infectious diseases and rare diseases, currently trading on NASDAQ under ticker IKT.
Profile data last refreshed 15h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Inhibikase Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Inhibikase Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Inhibikase Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$261K
Pipeline & Clinical Trials
Imatinib Mesylate
CMLClinical Trials (1)
NCT05623774A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
Phase 1Help build intelligence for Inhibikase Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.